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1. INTRODUCTION 
 
 
1.1 Antipsychotic drugs 
 
Antipsychotics medications are a class of drugs mainly used for the 
symptomatic treatment of psychosis including schizophrenia, mania, bipolar 
disorder and many other conditions characterized by agitation and altered 
mental status. A common feature of these drugs is the antagonistic activity 
at dopamine D2 receptors in the central nervous system but other receptors 
are involved in their mechanism of action including D1 and D4 in addition to 
serotonin (5HT), a-adrenergic, cholinergic and histaminic receptors (1). The 
first generation of antipsychotic agents, also designated as ‘neuroleptic’ or 
‘typical’, are potent dopaminergic D2 antagonists that have a strong 
propensity towards producing extrapyramidal side effects (EPSEs) arising 
from activity in the striatum. In contrast, the so-called newer generation of 
antipsychotics exhibits much less marked EPSEs and for this reason are 
named ‘atypical antipsychotics’ (APDs). 
 
1.1.2 The History 
Antipsychotic medications were pioneered by the development of 
phenothiazine compounds as industrial dyes (i.e. methylene blue) at the end 
of 19th century. Subsequently, in the 1930s, one of these compounds, 
promethazine, was found to have antihistaminic and sedative properties 
and, following tests on rodents, it was found to prolong sleep induced by 
barbiturates. It was introduced by Laborit in the clinic for its ability to 
prolong and stabilize anaesthesia for surgery (2). 
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A few years later, another significant phenothiazine derivative 
wassynthesized by Charpenter and later tested by Laborit. This compound, 
named chlorpromazine, was found to reduce anxiety and induce mild 
sedation without causing loss of consciousness, which led to its use in the 
treatment of psychosis in France by Delay and Deniker and later, 
chlorpromazine was licensed in the USA in 1955. 
The antidepressant and antipsychotic properties of promethazine 
were recognized in individuals using promethazine to treat topical infections 
(3Hood et al, 2007). Chlorpromazine, was developed in 1951, providing 
anticholinergic and antiemetic effects 17 (3). Then, the antipsychotic effects 
of chlorpromazine were appreciated. Haloperidol was developed in 1958, in 
a continued effort to refine the newly developed antipsychotic medications 
(3). 
 
1.1.3 First Generation Antipsychotics (Typical) 
 
Antipsychotics have been classified into two separate classes: typical 
and atypical. This distinction was originally made by the pharmaceutical 
companies while they sought to promote sales of the newly developed 
atypical drugs. 
The term “classic antipsychotic” is synonymous with “first generation 
antipsychotic” and “typical antipsychotic.” Typical antipsychotics are known 
for extreme sedation and causing severe extrapyramidal symptoms (3). 
Side effects can include:  
 acute and chronic movement disorders 
 increased prolactin levels 
 neuroleptic malignant syndrome 
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 anticholinergic symptoms 
 sedation 
 postural hypotension 
 reduced seizure threshold”  
Due to increases in prolactin levels, EPSE and worsening of negative 
symptoms, it became evident that the typical antipsychotics effects were 
limited to treating the positive symptoms of schizophrenia (Hood et al, 
2007).  
Typical drugs cause dyskinesias, including tardive dyskinesia. These are 
thought to arise from disruption to dopamine transmission in the basal 
ganglia. Atypical drugs have metabolic side effects. Although the exact 
consequence varies in degree from drug to drug, for example olanzapine 
may cause excessive weight gain-but not with all patients, while many 
atypicals cause diabetogenesis. 
The typical antipsychotics are commonly divided into three main 
categories that reflect different classes of chemical structure: (a) 
phenothiazine, (b) thioxanthines and (c) butyrophenones. 
First generation antipsychotics are also classified on the basis of their 
relative potency as low, medium and high potency, according to the dosage 
necessary to cause an antipsychotic effect. Aliphatic phenothiazines such as 
chlorpromazine are designated as ‘lowpotency’, while piperazine 
phenothiazines such as fluphenazine and trifluoperazine, thioxanthines and 
butyrophenones are referred to as ‘high potency’ antipsychotics. 
All the first generation antipsychotics antagonize the D2-subtype of 
dopamine receptors in the CNS. Although these drugs possess different 
affinities at D1, D4, serotonin 5HT2, histamine H1, adrenergic and cholinergic 
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receptors, it appears that D2 antagonism represents a major component of 
their antipsychotic activity (4). 
While dopamine is ubiquitous in the central nervous system, 
particularly in the nucleus caudate (nigrostriatal system), nucleus accumbens 
(mesocortical system), the mesolimbic system and the tuberoinfundibular 
pathway, dopamine D2 receptors localized in the limbic and striatal areas are 
implicated in antipsychotic efficacy and EPSEs. 
Due to the blockade of the dopamine D2 innervations in the striatum, 
the conventional antipsychotics generate a range of neurological adverse 
effects that are much less marked or even absent in the case of the newer 
generation drugs. While akathisia, dystonia, parkinsonism and neuroleptic 
malignant syndrome represent acute reactions to these medications, tardive 
diskinesia can occur after chronic treatment. 
Typical antipsychotics have long been recognized to elevate blood 
levels of the hormone prolactin. In fact, since the stimulation of the D2 
receptors in the tuberoinfindibular area suppresses prolactin release, all 
antipsychotics, particularly those acting in that brain area, cause some 
degree of hyperprolactinaemia via D2 antagonism. As a consequence, 
hyperprolactin-related side effects such as gynaecomastia, galactorrhoea 
and erectile dysfunction may occur. 
Allied to the high levels of prolactin induced by antipsychotics, these 
drugs are also subject of investigation with regard to their potential 
contribution to the development of bone mineral density loss, which has 
been reported in several studies (Liu-Seifert et al., 2004; Meaney et al., 2004; 
Meaney and O’Keane, 2007; Kishimoto et al., 2008) and breast cancer 
(Harvey et al., 2008). 
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Conventional first generation antipsychotics are not the current first 
choice for the treatment of schizophrenia and although they are effective in 
first-episode schizophrenia, especially in improving the positive symptoms, 
they are not superior to atypical agents such as clozapine (Lieberman et al., 
2003). Although chlorpromazine and haloperidol reduce the risk of relapse 
(Thornley et al., 2003; Joy et al., 2001), they are not effective in refractory 
schizophrenia compared to second-generation antipsychotics (Kane et al., 
1988). 
At present, treatment with typical agents is only recommended for 
patients showing a good clinical response with minimal side effects (Sharif, 
1998). 
 
1.1.4 Second Generation Antipsychotics (Atypical) 
The history of atypical antipsychotics began with the discovery of 
clozapine and its antipsychotic properties. 
In an effort to find a medication with less severe side-effects, 
clozapine was developed. This was the first “atypical” antipsychotic or 
“second generation antipsychotic”, and was found to be highly effective for 
treatment resistant schizophrenia. However, it posed the risk of 
agranulocytosis (3). Agranulocytosis is a granulocyte count less than 
500/mm3 in which the individual presents with signs and symptoms of 
infection (4). 
Three features of SGA (Second Generation Antipsychotics) include:  
 efficacy in treating positive symptoms 
 low incidence of EPSE and 5-HT2 serotonin receptor antagonism 
 D2 dopamine receptor antagonism 
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The clinical features of SGA including improvement in positive 
symptoms and negative symptoms, low incidence of EPSE after acute dosing, 
no elevation in prolactin, improved cognitive symptoms and improved mood, 
have shown benefit in treatment resistant patients. 
It is know known that Atypical drugs act on the 5HT2A receptor. They 
are not antagonists but inverse agonists, in effect causing a reversed effect. 
They also act upon a range of other receptors, but the respective affinities 
vary from drug to drug. In sharp contrast to haloperidol, drugs like 
risperidone have a weak potential to cause injury to cells. These atypical 
drugs also cause neurogenesis (5). 
Studies with clozapine have shown that pretreatment and post 
treatment reverse the effects of haloperidol toxicity (5). In addition, the drug 
can increase NGF plasma levels in medication naïve schizophrenia patients. 
The level of NGF is increased to approximately normal levels. Although this 
presents a possibility of using neurotrophins to treat schizophrenia, it is 
important to remember that while we can stimulate neurogenesis, we 
cannot ensure that the proper connections are made. 
Atypical drugs have other effects that are in opposition to haloperidol, 
and these actions promote cells survival. Atypical drugs reduce caspase 
activation (6), block glutamate toxicity and ameliorate rotenone induced 
toxicity. 
Clozapine was introduced to the market in the 1960s and while the 
chemical structure first suggested that it might posses a potential effect as 
an antidepressant, it was soon discovered that it actually had neuroleptic 
properties. However, there was an anomaly reported about this finding 
because clozapine yielded antipsychotic activity without causing EPSEs and 
this stimulated interest in the nature of this drug. In fact, at that time, the 
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onset of EPSEs was considered an inseparable pre-requirement for 
antipsychotic activity (7). 
Nevertheless, clozapine was marketed in several European countries 
until a study conducted in Finland in 1975 reported several cases of 
agranulocytosis resulting from treatment (8). Clozapine was then withdrawn 
from the clinical use, but in the following years its unique properties were 
extensively investigated until the validation of its efficacy in treating 
resistant-schizophrenia was established, leading to the reappearance on the 
market in 1990. 
Soon after clozapine returned to the market, a new generation of 
antipsychotic drugs, called ‘atypical’, was developed and marketed. Amongst 
these olanzapine, quetiapine, risperidone, ziprasidone and aripiprazole were 
introduced into clinical usage. 
Side Effects of Second Generation Antipsychotics SGA have been 
noted to improve adherence due to more tolerable side effects, in 
comparison to the side effects associated with FGA (9). Although SGA are a 
new addition to the available treatments for bipolar and schizophrenia, their 
side effect profile has been appreciated. It is possible that the side effects of 
SGA may not be less serious than those of FGA. Issues that present with SGA 
use include metabolic disturbance, weight gain and QT prolongation (9).  
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Table 1: side effects of typical and atypical antipsychotics 
 
 
 Metabolic Disturbance and Weight Gain: 
With the use of SGA, weight gain and increased appetite are noted as 
prominent side effects (Stahl, 2008). As a result, obesity and an increase in 
BMI can result; thus, increasing an individual’s cardiometabolic risk, 
predisposing one to a premature death (Stahl, 2008). The H1 histamine 
receptor and the 5HT2C serotonin receptor in the brain are associated with 
weight gain in the use of SGA. When blocked, especially synchronously, 
individuals taking SGA can experience weight gain (10). The hypothalamic 
centers are also partially responsible for enhancing appetite (10).The risks to 
cardiovascular health as a result of SGA treatment are equivalent to the risks 
of cigarette smoking (Bell et al., 2009).  
Patients treated with SGA have an increased risk of diabetes mellitus, 
high blood pressure, coronary heart disease and related conditions (11). In 
addition, variables including patient’s age, family history, lifestyle, smoking 
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and exercise play an important role in the evaluation of metabolic syndrome 
(Bell et al., 2009, p. 142). 
SGA weight gain varies according to baseline BMI. If the patient is 
obese, thus having a higher BMI, prior to the initiation of SGA treatment, the 
patient will not gain as much weight as their counterpart with a lower 
BMI(12). Among the SGA, clozapine and olanzapine have the highest 
association with metabolic disturbance (13). 
Second generation antipsychotics have also been found to induce a 
preference for carbohydrate foods (14). Following an initial weight gain 
during the first few months of therapy, an individual taking SGA can continue 
to gain weight even after one year of discontinuation of treatment (14). 
Patients on olanzapine who gain two to three kilograms within the first few 
weeks of treatment present a significant risk for long term weight gain (14). 
Clozapine, olanzapine and risperidone are three SGA that have been 
associated with the greatest weight gain.  
 
1.1.5 Metabolic adverse effects 
Metabolic adverse effects associated with antipsychotics are of 
particular concern because of the increase in cardiovascular morbidity and 
mortality.4 Olanzapine and clozapine are particularly associated with 
substantial weight gain, dyslipidaemia and hyperglycaemia.4 People taking 
these medicines often report that they always feel hungry. Weight gain can 
be substantial – a gain of 2 kg in two weeks should prompt a medicine 
review. All patients prescribed antipsychotics should be given appropriate 
advice on diet and lifestyle interventions and monitored carefully for 
diabetes. 
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1.1.6 Extrapyramidal effects 
Atypical antipsychotics are generally considered to cause fewer 
extrapyramidal adverse effects than typical antipsychotics. A meta-analysis 
showed clozapine, olanzapine and risperidone to be significantly less 
commonly associated with extrapyramidal symptoms than low potency 
typical antipsychotics (i.e. chlorpromazine 600 mg daily or equivalent).8 The 
majority of studies have found no differences within the atypical group in 
terms of extrapyramidal effects. 
 
1.1.7 Tardive dyskinesia 
Rates of new-onset tardive dyskinesia (orofacial and trunk 
movements) have been estimated at 3% with risperidone and 1% to 2% for 
other atypical antipsychotics. In comparison, tardive dyskinesia develops in 
around 20% of people receiving typical antipsychotics. Tardive dyskinesia is 
of particular concern as it may not be evident immediately, is often resistant 
to treatment, may be persistent and may worsen on treatment withdrawal. 
 
 
1.2 Schizophrenia 
 
In the general population, approximately 1% suffers from 
schizophrenia. This chronic disorder often manifests in youth, and are 
characterized by a number of symptoms, all of which can be classified as 
either positive (paranoid delusions, auditory hallucinations, thought 
disorders etc.), negative (flattened affect, apathy, social withdrawal etc.) or 
cognitive symptoms (reduced sustained attention and executive functions). 
Even though all of these symptoms are evident in different cases of 
schizophrenia, none of the symptoms is pathognomonic for schizophrenia.  
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1.2.1 The etiology of schizophrenia 
Genetics play a key role in schizophrenia, but the exact etiology of 
schizophrenia remains largely unknown. Through the last decades, different 
Original article causes of schizophrenia have been investigated, including 
changes in neurotransmitter systems and neurodevelopment abnormalities. 
The dopamine hypothesis was first described in the 1970’s,. Evidence of 
correlation between blockade of dopamine D2 receptors (DRD2), and 
response to antipsychotic drugs lead to a theory of dopamine hyperfunction 
in subcortical regions (nucleus accumbens) in the brain (7). Subcortical 
regions are dense in DRD2, and the number of DRD2 have been shown 
further increased in these areas in schizophrenia8. The dopamine 
hyperfunction in the limbic system are considered responsible for the 
positive symptoms of schizophrenia (7). Since the 1970’s, the hypothesis has 
been refined to include a dopaminergic hypofunction in the prefrontal cortex 
(9). The prefrontal cortex is an area dense in dopamine D1 receptors, in 
which abnormalities may account for the negative symptoms as well as the 
cognitive impairment of schizophrenia. More recently, studies suggests that 
dopamine activity can be influenced by abnormalities in glutamate 
transmission in areas such as substantia nigra and the ventral tegmental 
area. Deficiency of Nmethyl aspartate (NMDA) transmission, a receptor of 
glutamate, can lead to a hypofunction of dopamine receptors in the 
prefrontal cortex, subsequently leading to a decrease in mesocortical 
dopamine transmission. Over time, the deficiency of the meso-limbic 
dopamine transmission might cause the positive symptoms of schizophrenia. 
N-desmethylclozapine (NDMC) Clozapine undergoes hepatic metabolization 
by several P450 CYP enzymes, the most significant being CYP1A2, CYP2D6 
and CYP3A410. The high first pass metabolism reduces the bioavailability of 
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clozapine to 50-60%. The majority of clozapines metabolites are 
physiological inactive, but N-desmethylclozapine (NDMC) is active. Only a 
few studies have investigated the effects of NDMC, but studies suggest 
different properties of NDMC than clozapine (14-16). NDMC acts as an 
partial agonist to DRD2 (14), with a binding affinity (Ki) of 115, (17). 
Clozapine on the other hand, acts as an inverse agonist, or antagonist (15) 
with a Ki of 431 (17). An animal study evaluating Conditioned avoidance 
responding and Amphetamine-induced locomotion, models of antipsychotic 
efficacy, has revealed differences between clozapine and NDMC. Clozapine 
inhibited effects in both models, the inhibition were only present at high 
dosages of NDMC (16). A model of regional activation of the central nervous 
system (Fos expression), showed both clozapine and NDMC ability to induce 
Fos in nucleus accumbens but not in the dorsolateral striatum. Again, NDMC 
required high dosages to do the same (16). No differences between 
clozapine and NDMC in studies investigating catalepsy (measure of motor-
side effects) or prolactin measurement (measure of side-effects) were found 
(16). Treatment of schizophrenia In most cases of schizophrenia, 
antipsychotic drugs are the treatment of choice (18). However, 
discontinuation of treatment is a common obstacle in this patient group, due 
to side-effects or lack of efficacy, the latter one also leaving a large 
proportion of patients symptomatic despite adequate antipsychotic 
treatment (19). Up to 30% of patients suffering from schizophrenia, are 
classified as treatment resistant schizophrenia (TRS) (20). TRS are often 
defined as inadequate response to two, or more first generation 
antipsychotics (FGA) and second generation antipsychotics (SGA). 
Clozapine is the most efficient antipsychotic drugs, proven efficient for 
alleviating both positive and negative symptoms (21), as well as having 
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antisuicidal properties. On the other hand, studies fail to find any substantial 
superiority of clozapine compared to other dopamine antagonists in first 
episode schizophrenia, suggesting a biological homogeneity of patients 
responding to clozapine. Clozapine is not considered a first line antipsychotic 
drug in non-resistant schizophrenia, due to the risk of agranulocytosis and 
myocarditis (26). The side-effects warrant close monitoring of patients (26). 
Nevertheless, clozapine posses the unique property of being efficient in 3 
Original article approximately 50% of patient with TRS, making it the golden 
standard for treating TRS.  
The mechanism of action of clozapine is unknown, but several theories 
exist; I) Dysregulation of the immune system have been observed in 
schizophrenia (28), and preclinical studies suggest that improvements by 
clozapine in factors influencing the immune systems, correlates with 
symptoms relieve. Thus, a theory of an antiinflammatory effect of clozapine 
was proposed as being the reason for the unique effect. II) Evidence of 
clozapine affinity towards a large number of receptors has been 
acknowledged for a long time (30). The high affinity of clozapine to 
muscarinic receptors, a property mainly clozapine possess, lead to a theory 
that the receptor might be an important factor in clozapine response (32). III) 
Blockage of DRD2 is a shared feature of all present antipsychotic drugs (7). 
In addition, a DRD2 occupation of at least 70% is considered optimum 
for antipsychotic response. Interestingly, the high occupancy is not the case 
for clozapine, which rarely reaches occupancy of 70% even at high dosages. 
Clozapine superior effectiveness might be caused by regional selectivity, 
since clozapine specifically target DRD2 in limbic and cortical regions. In 
addition, clozapine display a fast dissociation rate and are more loosely 
bound to DRD2, unlike other antipsychotic drugs (5). 
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1.3 PKC Structure, Classification, and Regulation  
 
Protein Kinase C is Ca2+ activated, defined by a structurally related 
family of serine/threonine protein kinases that are involved in several 
biological processes including proliferation, differentiation, apoptosis, 
adhesion and migration. All members contain a highly conserved kinase 
domain and regulatory domain. The kinase domain resides in the C-terminal 
half of the protein and consists of motifs that are required for ATP/substrate 
binding and catalysis. The regulatory domain is contained within the amino 
terminal half of the protein and is defined by an auto-inhibitory pseudo-
substrate domain and one or two discrete membrane targeting domains; a 
C1 domain that binds diacylglycerol (DAG) or phorbol ester, and a C2 domain 
that binds Ca2+ (15). This family is sub-classified into three groups of 
isoforms based on their cofactor requirements for activation and 
corresponding structural differences in their regulatory domain (16). 
 
The three subclasses are:  
1) conventional PKCs (cPKCs) that contains both a C1 domain that 
functions as a DAG binding site and a C2 domain that binds Ca2+;  
2) novel PKCs (nPKCs) are structurally similar to the cPKCs, except that 
they lack a Ca2+ binding site but can be stimulated by DAG; 
3) atypical PKCs (aPKCs) also lack a Ca2+ -binding C2 domain and have an 
atypical C1 domain that makes them insensitive to DAG but responsive 
to other lipids such as arachidonic acid and ceramide.  
The group of conventional PKC isoforms is the most highly studied and 
best understood subclass. The PKC family transduces cell signals by 
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promoting lipid hydrolysis (17). Many known membrane receptors transmit 
intracellular signals through activation of PKC (18). 
An external signal activates a G-ProteinCoupled Receptor (GPCR), 
which activates the GTPase enzyme phospholipase C (PLC). PLC cleaves 
phosphoinositol-4,5-bisphosphate (PIP2) into DAG and inositol-1,4,5- 
trisphosphate (IP3). IP3 interacts with a calcium channel in the endoplasmic 
reticulum (ER) thereby triggering the release of Ca2+ into the cytoplasm. The 
increase in Ca2+ levels activates cytoplasmic PKC which translocates to the 
membrane and is anchored to the plasma membrane via DAG and 
phosphatidylserine (PS). Activated PKC isoforms phosphorylate protein 
substrates in the membrane and cytosol to propagate signals throughout the 
cell that culminate in various biological and cancer-related phenotypes. 
 
 
Figure 1: Schematic representation of protein kinase C isozyme structure and classification  
 
 
18 
Many known membrane receptors transmit intracellular signals 
through activation of PKC (Kenny et al., 2007; Lee and Bell, 1991). One 
known pathway for PKC activation is described in (Koivunen et al., 2006). An 
external signal activates a G-ProteinCoupled Receptor (GPCR), which 
activates the GTPase enzyme phospholipase C (PLC). PLC cleaves 
phosphoinositol-4,5-bisphosphate (PIP2) into DAG and inositol-1,4,5-4 
trisphosphate (IP3). IP3 interacts with a calcium channel in the endoplasmic 
reticulum (ER) thereby triggering the release of Ca2+ into the cytoplasm. The 
increase in Ca2+ levels activates cytoplasmic PKC which translocates to the 
membrane and is anchored to the plasma membrane via DAG and 
phosphatidylserine (PS). Activated PKC isoforms phosphorylate protein 
substrates in the membrane and cytosol to propagate signals throughout the 
cell that culminate in various biological and cancer-related phenotypes.  
PKC is a member of the larger group of serine/threonine kinases that 
contain protein kinases G and A, among others and is widely expressed 
throughout the body. The family of PKCs is made up of ten different 
isoforms, classified into three groups based on their regulatory domains. The 
conventional PKCs (α,βI,βII and γ) require diacylglycerol, calcium, and 
phospholipids for activation. Finally, the atypical PKCs (ζ,ι/λ) require anionic 
phospholipids for activation instead of either calcium or diacylglycerol. 
Within the brain, PKC interacts with neurotransmitters via several 
mechanisms, interacting with ion channels and increasing the vesicle pool 
(19,20) As a result, PKC activity increases the release of many 
neurotransmitters, including dopamine (21), norepinephrine (22), and 
glutamate (23). PKC regulates both D2R and DAT through phosphorylation. 
The N-terminus of DAT contains a series of serines that are phosphorylated 
by PKC (24). Removal of these serines either via mutation to non-
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phosphorylatable alanines or truncation of the N-terminus abolishes the 
amphetamine-stimulated efflux of dopamine through DAT without altering 
the normal uptake process. D2R is phosphorylated by PKC on the third 
intracellular loop causing internalization and desensitization of the receptor 
(25). Additionally, PKC β activity is required for amphetamine-stimulated 
dopamine efflux through the use of specificPKCβ inhibitors (26).  
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2. MATERIALS AND METHODS 
 
 
2.1 Cell cultures 
 
2.1.1 MDSCs (muscle derived sem cells) 
Primary cultures of MDSCs were prepared from newborn mice wild 
type and PKCβ null (2–3 days) as described in Brini et al. Adipogenic 
conversion was observed both in the first preplating (15 min) and in the 
replating of non-rapidly adherent cells. For this reason, the first pool of 
adherent cells was used for all experiments. The viable cells obtained were 
counted using the Trypan blue exclusion assay and were seeded at a density 
of 10 × 105 cells per square centimeter for in vitro expansion in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with glucose 25 mM for 5 
days. At day 5, APDs (clozapine, olanzapine; quetiapine, risperidone and 
aripiprazole (250 mM)) were added for the following 3 days. The DMEM 
without the addition of high glucose (low glucose) was used as a negative 
control. 
 
2.1.2 ADSCs (Adipose-derived stem cells) 
ADSCs were extracted from human adipose tissues of five healthy 
female patients undergoing cosmetic surgery procedures, following 
guidelines from the Clinic of Plastic Surgery, University of Padova. Adipose 
tissues were digested with 0.075% collagenase (type 1A; Sigma–Aldrich, 
Milan, Italy) in modified Krebs–Ringer buffer for 60 min at 37 °C followed by 
10 min with 0.25% trypsin. The viable cells obtained were counted using the 
Trypan blue exclusion assay and seeded at a density of 1 × 106 cells per 
square centimeter for in vitro expansion in DMEM supplemented with 
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glucose 25 MM after 5 days of expansion. At day 5, APDs were added for the 
following 3 days. DMEM without the addition of high glucose (low glucose) 
was used as a negative control. 
 
2.1.3 Morphological analysis 
Morphological cell analyses to determine the extend of preadipocyte 
differentiation were performed using a phase-contrast microscope at a 10x 
magnification, counting cells in the field of vision, randomly chosen. Five 
fields were counted. Main morphological criteria for differentiation were an 
increasing number and size of visible lipid droplets as well as a change in 
morphology from elongated contours to a round shape. 
 
2.1.4 Oil Red O staining 
To determine the Adipose Differentiation Oil Red O staining was 
performed according to a method by Zacarias et al. Monolayer cultures were 
washed with PBS and fixed with cold 10% paraformaldehyde and incubated 
for five hours at 4 °C. Oil Red O working solution (0.5 g in 100 ml 
isopropanol) was added to culture flasks for two hours at room temperature. 
After washing, stained cells were kept in 10% paraformaldehyde and 
examined by light microscopy. 
 
3.1.4 Microscopic analysis of PKC translocation 
The cells were seeded before transduction onto 24 mm glass coverslips 
and allowed to grow to 50% confluence. At this stage, images of PKC-β 
translocation were obtained with digital imaging system, at 24 h after 
infection with adenovirus PKC-β–green fluorescent protein chimera. At 24 h 
after infection, the medium was changed from DMEM and 10% fetal calf 
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serum to Krebs–Ringer buffer. Images were recorded using a digital imaging 
system based on a Zeiss Axiovert 200 (Arese, Milan, Italy) fluorescence 
microscope equipped with a back-illuminated charge coupled device camera 
(Roper Scientific, Trenton, NJ, USA), excitation and emission filterwheels 
(Sutter Instrument Company, Novato, CA, USA) and piezoelectric motoring of 
the z-stage (Physik Instrumente, GmbH & Co., Germany) for rapid focusing in 
the z-plane. The data were acquired and processed using the MetaMorph 
analyzing program (Universal Imaging Corporation, Downington, PA, USA). 
This allows the direct monitoring of fluorescence intensity. A high-resolution, 
three-dimensional reconstruction of the distribution of a green fluorescent 
protein chimera can be obtained with the technique of digital image 
restoration, also called deconvolution or deblurring. The graph indicates the 
plasma membrane of PKC-β–green fluorescent protein expressed as the 
increase in fluorescence ratio with respect to time zero (calculated as a ratio 
of plasma membrane/cytosol average fluorescence). Averaging results are 
representative of at least three independent experiments. 
 
 
2.2 Animals 
 
Animals employed in all procedures were male mice at the age of 4-6 
weeks. Prior to any experimental procedures, mice were either group-
housed or isolated randomly (depending upon the experimental protocols). 
They were kept under constant conditions: 12/12 h light /dark cycle (light on 
0800 hours), temp (24 ᵒ C) and humidity (54 –60%) in our laboratory facility.  
In all cases, mice were fed with 12 g of high fat feed (60% of fat) 
obtained from Harlan Laboratories(lotto: 222140). 
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The weight of the animals was monitored every day. 
Daily access to feed, water and Clozapine was ad libitum. In all 
procedures, the mice were left under specified conditions to acclimatize for 
at least three weeks before conducting any experimental procedures. Mice 
were properly handled by the experimenter and made familiar to gavage 
administration during the specified periods. All experiments employed were 
done in accordance with the European Communities Council Directive of 24 
November 1986 (86/609/EEC) and were approved by the local council of 
animal care (University of Ferrara).  
 
Groups of animals 
A: male mice C57BL/6J – control group  
B: male mice C57BL/6J – treated with Clozapine (Haxal AG, Germany) 
C: male mice PKCβ null - control group 
D: male mice PKCβ null - treated with Clozapine (Haxal AG, Germany) 
E: male mice C57BL/6J - treated with the pharmacological inhibitor of 
PKCβ (LY33351, Eli Lilly & Co. (Indianapolis, IN)). 
D: male mice C57BL/6J- co-administration of Clozapine and the 
pharmacological inhibitor of PKCβ 
 
 
2.3 Drugs 
 
Drugs and chemicals employed in this dissertation were scientifically 
proven quality and from known sources. 
Clozapine (Hexal AG, Germany) was administrated orally, diluted in 
drinking water (25mg of Clozapine in 100ml of drinking water). Twice a week 
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the water containing the Clozapine was changed. The long – term treatment 
with this drug had a maximum duration of five months.  
Pharmacological Inhibitor of PKCβ (LY33351- Eli Lilly & 
Co.,Indianapolis, IN)  
Ruboxistaurin was submitted for approval in Europe in the second 
quarter of 2006. The agent is also in phase II studies for the treatment of 
diabetic maculopathy (macular retinopathy) in Japan. Data from a phase III, 
3-year study of ruboxistaurin in patients with moderate to severe diabetic 
retinopathy showed that ruboxistaurin markedly reduced the risk of 
sustained vision loss compared with placebo. This multicentre, randomised 
study, named PKC-DRS2 (Protein Kinase C-Diabetic Retinopathy Study 2), was 
conducted at 70 clinical sites and involved 685 patients with diabetic 
retinopathy. The agent is also in a phase II study in the US, Canada and 
Europe in patients with clinically significant macular oedema. 
 
 
2.4 Treatments 
 
2.4.1 Long-term treatment with Clozapine and Weight gain monitoring  
Male mice of the age of 4-6 weeks were used for all the experiments 
of weight monitoring. The animals of the treated group with Clozapine, have 
had as only source of water the Clozapine diluted in drinking water, always 
at the same concentration during the experiment.  
The first data obtained in our laboratory are referred to a three month 
treatment and then repeated with five month duration due to verify if the 
weight gain and the motor phenotype persist after long periods of 
treatment. 
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Treatment with the pharmacological inhibitor was performed using 
the technique of oral dose (Gavage). 
 
2.4.2 Oral Dosing (Gavage) in Mice 
In order to administer the pharmacological inhibitor of PKCβ oral-
gavage was employed daily for duration of three months. During this period 
of time the mice were also orally treated with Clozapine. 
In order to obtain valid data on monitoring the weight gain, the 
control group of mice was treated by using the oral-gavage with drinking 
water and induce the same leves of stress in all the groups of animals. 
This Standard Operating Procedure (SOP) describes the procedure of 
orally dosing rats and mice. This SOP follows the UBC and CCAC guidelines 
for acceptable oral dose volumes in rodents (UBC Animal Care Guidelines). 
 
Materials  
- Correctly sized feeding needles (see chart below)  
- Appropriate sized syringes  
- Solution to be administered  
 
Procedure 
1. Calculate the maximum volume that can be administered to the 
animal. Oral dosing volumes should not exceed 10ml/kg. 
2. Prior to performing the oral dosing procedure, measure the distance 
from the oral cavity to the end of the xyphoid process (caudal point 
of the sternum) with the feeding needle on the outside of the 
restrained animal. This will be how far the needle will be inserted 
into the esophagus. 
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3. With the feeding needle attached to the filled syringe, slide the end 
of the feeding needle along the roof of the animal’s oral cavity 
towards the animal’s left side. The feeding needle should slide down 
the esophagus with gravity alone. There should be no resistance 
when passing the feeding needle. The gavage needle may rotate 
clockwise slightly as it passes the epiglottis and into the esophagus. 
The animal may gag when the needle is passed; this is normal. If 
there is any resistance or if the animal struggles excessively remove 
the feeding needle, ensure you have good restraint on the animal 
and attempt to pass the needle again. 
4. Do not at any time force the needle down the esophagus, this may 
cause tears to the esophagus, injury to the animal, or you may 
inadvertently force the needle down the trachea. 
5. Once the feeding needle is in to the premeasured distance, slowly 
inject the solution to minimize the fluid coming back up the 
esophagus. There should be no resistance while injecting – the 
needle will be in the distal esophagus, not the stomach. 
6. Remove the feeding needle in the opposite direction from insertion 
and return the animal to its cage. 
7. Monitor the animal for potential complications 
 
 
Figure 2: Oral Gavage in mice. 
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2.5 Motor Activity  
  
2.5.1 Open Field Measurement 
To examine a motor response thought to be related to the negative 
effect of clozapine tests of measurement of motor activity Horizontal and 
vertical locomotion of mice were assessed using an open-field box (Fig.). In 
the open field boards, the behaviour was first videotaped and later offline 
monitored using a dose-based program. In the activity box, locomotion was 
monitored using a fully automated computer controlled photocells (Process 
control motility test 302000, TSE, Technical and Scientific Equipment). 
Interruptions of horizontal and vertical light beams due to mouse’s 
movement were registered automatically. These data were then later 
converted to digital values, expressed as distance travelled in meter or 
number of rearing. 
 
 
Figure 3: Schematic presentation of open-field box (A) and activity box (B) 
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2.5.2 Rotarod test 
The akinetic/bradykinetic effects of Clozapine on mice behaviour were 
evaluated through the Rotarod test, mice were placed on a 6 cm diameter 
rod (Model 720A, IITC/Life Science Instruments, Woodland Hills, CA) that 
was rotating at 10 revolutions per minute. The amount of time spent on the 
rod before falling off was measured in two consecutive trails with a 2 min 
break between trials. Data represent the average time spent on the rod 
during these trials.  
 
 
Figure 4: Rotarod Test 
 
2.5.3 Bar Test 
This motor test was applied to mice, due to evaluate the Akinetic 
phenotype or catalepsy induced by the treatment of Clozapine. 
Catalepsy is manifested as a physical condition usually with catatonic 
schizophrenia, characterized by suspension of sensation, muscular rigidity, 
fixity of posture, and often by loss of contact with the environment. 
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Figure 5: bar test 
 
2.5.4 Drag test 
This test measures the ability of the animal to balance its body posture 
with the forelimbs in response to an externally imposed dynamic stimulus 
(backward dragging). It gives information regarding the time to initiate and 
execute (bradykinesia) a movement. Animals were gently lifted from the tail 
leaving the forepaws on the table, and then dragged backwards at a constant 
speed (about 20 cm/s) for a fixed distance (100 cm). The number of steps 
made by each paw was recorded. Five to seven determinations were 
collected for each animal. 
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3. RESULTS 
 
 
3.1 Clozapine induces Differentiation in vitro  
 
Adipose derived stem cells have been evaluated in terms of lipid 
production after treatment with different APDs. The results obtained with oil 
red quantification are reported in term of percentage varation compared to 
the high-glucose medium set to 100%. 
 
 
Graphic 1: APDs are able to increase the total lipid production on ADSCs: Clozapine and 
Quetiapine show a clear difference in terms of lipid production. Aripripazole induces lipid 
production comparable to that observed in untreated cells 
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3.2 APDs induce PKCβ activation in Vitro  
 
The endogenous PKCβ is mostly cytosolic under low-glucose 
conditions. Incubation for 1h with Clozapine induced notable translocation 
of the kinase into the plasmamembrane, it’s typical localization after 
activation. The ratio of the detected signal in cytoplasm when compared to 
plasmamembrane showed a kinetic directly related to Clozapine treatment. 
 
PKC membrane translocation 
Clozapine 
  
Figure 6: PKC membrane translocation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 min. 60 min. 
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3.2.1 Weight gain monitoring of wiled type mice treated for three months 
with Clozapine 
Wild type mice were treated for three months with Clozapine. Daily 
monitoring of the weight during this period of time revealed a significant 
weight gain of the animals. The results are expressed as Δ of weight gain and 
kinetics during the experiment. 
 
 
 
Clozapine chronic treatment in WT mice:  
i) treated mice present a significative major Δ weight gain against controls  
ii) Traces of weight gain kinetics during the chronic administration of Clozapine for 12 weeks, 
present significative differences only the last 2 weeks of the experiment  
 
Graphic 2: Weight gain in wild type mice during 20 weeks of treatment with clozapine 
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3.2.2 Weight gain monitoring of PKCβ null mice treated for three fine with 
Clozapine 
The data shown are referred to PKCβ null mice treated for three 
months with Clozapine. No significant weight gain in the treated mice was 
demonstrated. 
 
 
Clozapine chronic treatment in PKCβ null mice:  
i. treated and untreated mice have no significative variance in weight gain  
ii. Traces of weight  gain kinetics during the chronic administration of Clozapine for 12 weeks 
treatment. Treated animals present no significant differences vs controls  
 
Graphic 3:  Weight gain in PKCβ mice during 20 weeks of treatment with clozapine 
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3.2.3 Motor phenotype of the mice treated with Clozapine 
 
Motor Activity of wiled type mice treated with clozapine 
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Motor Activity of PKCβ null mice treated with clozapine 
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Graphic 4: Effect of chronic administration of CLOZAPINE in the bar (A), drag (B) and 
rotarod (C) tests in mice. Data are expressed as time on bar (A), number of steps (B) and 
time on the rod (C) and are means ± SEM of 4-5 determinations per group. *p<0.05, ** 
p<0.01 significantly different from control  
 
 
 
 
 
 
 
35 
3.3 Co-treatment of Clozapine and the Pharmacological inhibitor of 
PKCβ 
 
The results indicate that the inhibition of PKCβ protects against the 
weight gain during the treatment with Clozapine. Motor tests are exhibit to 
prove that the antipsychotic effect of Clozapine persists even with the 
administration of the pharmacological inhibitor. 
 
 
*p<0.05 toCTRL, •p< 0.05 to CLZ  
i) Δ of the weight gain in mice treated with Clozapine and co- administration of the 
Pharmacological inhibitor of PKCβ (of LY-333,351)  
ii) Weight gain kinetics, significance: * expressed to controls, • expressed to clozapine  
 
Graphic 5: Co-treatment of Clozapine and the Pharmacological inhibitor of PKCβ 
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Motor Activity of wiled type mice treated with Clozapine and the pharmacological inhibitor 
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Graphic 6: Effect of chronic administration of CLOZAPINE in the bar (A), drag (B) and 
rotarod (C) tests in mice. Data are expressed as time on bar (A), number of steps (B) and 
time on the rod (C) and are means ± SEM of 10-17 determinations per group. *p<0.05, ** 
p<0.01 significantly different from control  
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4. DISCUSSION 
 
Atypical antipsychotics (APDs) are currently used in clinical practice for 
a variety of mental disorders (schizophrenia, bipolar disorder, severe 
behavioral disorder) presenting as  common side effects the weight gain, 
obesity, lipid abnormalities and diabetes. 
Our previous studies in vitro on adipogenic events, show that in cell 
cultures of human pre-adipocytes and rat muscle-derived stem cells, where 
APDs (clozapine, olanzapine, quetiapine, risperdione and aripiprazole) were 
added in the presence of high glucose, presented an increase in lipid 
accumulation and an enhancement of pre-adipocyte differentiation.  
Our data show that Protein Kinase C isoform β (PKC β) has a crucial 
role in the metabolic pathways leading to the neo-differentiation of adipose 
cells during APDs treatment. Through pharmacological inhibitor (hispridin) 
and molecular silencing we have prevented the APDs-induced lipid 
accumulation, providing its direct involvement into this process. 
Clozapine can active adipogenesis through PKC-β translocation to 
plasma membrane and activation. 
Based on these data, in vivo experiments were carried on. A 
pharmacological inhibitor  (LY333531-mesylate) of PKC-β is oral administered 
in wild type mice treated with clozapine. Our study indicates that the mice 
treated with clozapine and in addition with the inhibitor present in the 
behavioral tests decreased time spent resting and reaching distances. 
In the last three months, our experiments in vivo, are focused in PKC-β 
-/- mice, treated with clozapine, so we can monitor their behavior and 
weight gain and compare it to our control animals. At present, our data 
support the previous findings, showing that the PKC-β knock out mice 
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treated with clozapine and those not treated present the same rate of 
weight gain. These findings underline the crucial role of PKC-β protein in 
weight gain, when APDs are administrated in animal models. 
Atypical antipsychotics (APDs) are currently used in clinical practice for 
a variety of mental disorders (schizophrenia, bipolar disorder, severe 
behavioral disorder) presenting as  common side effects the weight gain, 
obesity, lipid abnormalities and diabetes.  
Our previous studies in vitro on adipogenic events, show that in cell 
cultures of human pre-adipocytes and rat muscle-derived stem cells (ADSCs), 
where APDs (clozapine, olanzapine, quetiapine, risperdione and aripiprazole) 
were added in the presence of high glucose, presented an increase in lipid 
accumulation and an enhancement of pre-adipocyte differentiation.  
Our data show that Protein Kinase C isoform β (PKC β) has a crucial 
role in the metabolic pathways leading to the neo-differentiation of adipose 
cells during APDs treatment. The pharmacological inhibition and the 
molecular silencing of PKC-β prevent the APDs-induced lipid accumulation, 
providing its direct involvement into this process.  
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